NYSE:Global Blood Therapeutics, Inc.

График котировок Global Blood Therapeutics, Inc.


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 31.2
P/BV 5.85
EV/EBITDA -8.03
EBITDA -0.29
Цена ао 46.94

Основные владельцы

Institutions Объем Доля, %
First Trust Portfolios L.P. 45691 0.07
Hennion & Walsh, Inc 500 0
Janus Capital Management LLC 5996305 9.7
Logos Global Management LP 850000 1.38
Nicholas Investment Partners 11983 0.02
Asymmetry Capital Management, L.P. 155232 0.25
CT Mason 124749 0.2
Security Investors, LLC 80430 0.13
Fernwood Investment Management, LLC 187477 0.3
Perceptive Advisors LLC 5800996 9.39
First Midwest Bank 14582 0.02
John Hancock Investment Management LLC 221913 0.36
Botty Investors LLC 217510 0.35
Fidelity Management & Research Company LLC 3717701 6.02
Pharmakon Advisors L.P. 653414 1.06
BNP Paribas Asset Management Luxembourg 280239 0.45
AQA Capital Limited 5000 0.01
Fidelity Investments 381839 0.62
Great Point Partners LLC 655676 1.06
Hennion & Walsh, Inc 500 0
Munder Lee Investments Ltd 20405 0.03
Fidelity Management & Research Company LLC 3431107 5.55
Fidelity Investments Canada ULC 25678 0.04

Похожие компании

Описание Global Blood Therapeutics, Inc.

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.